Kurt Seiler

Since October 1st, 2014 Kurt Seiler is Global Head of Compliance at Roche Diabetes Care. He has built up a global Compliance Organization and Compliance Processes throughout this global Business.


In 26 years with Roche he has held many executive management positions around the world:

  • Chief Information Officer Roche Diabetes Care, based in Basel, Switzerland
  • Head of Customer Services EMEA LATAM for Roche Diabetes Care, based in Mannheim, Germany
  • Head of IT North America for Roche Diagnostics, based in Indianapolis, USA
  • Head of IT Asia Pacific for Roche Diagnostics, based in Sydney, Australia and Singapore.
  • Head of IT Corporate Finance, based in Basel Switzerland 

Kurt Seiler holds a diploma in Mathematics and a doctorate in Theoretical Physics from ETH Zurich and an MBA from the University of Zurich.

In an era where transparency is expected, the healthcare industry has been at the centre of attention from the public and from authorities. We can see this in how governments around the world – notably the US and France – have developed ‘Sunshine Acts’ to mandate disclosure of industry support for healthcare institutions and professionals. These transparency laws can take differing approaches, posing challenges to companies. On the other hand, Europe’s medtech industry is committed to self-regulation as means of building public trust. We believe that by notably setting a high and common standard for transparency, we can meet public expectations. So, what have we achieved so far? We are pleased to report that our industry has taken several steps forward to improve transparency and enhance our reputation as an ethical business. We have embraced a Code of Ethical Business. A key element of the Code is the ban on direct sponsorship of health professionals. We have shifted towards a model of educational grants, which reinforces our commitment to supporting medical education, whilst providing transparency, as these educational grants are subject to disclosure on a Europe-wide platform . In devising this approach, we learned some lessons from the experience of the pharmaceutical industry which discloses all transfers of value to healthcare professionals on companies’ own websites. Under the pharma model, companies are required to secure health professionals’ consent to disclose information and, in the absence of a European-wide platform, it can be cumbersome for the public to access information on transfers of value. In medtech, we have removed the burden of handling consent management and reduced the burden for the public by making information available in one place. But the lack of convergence between these two approaches poses challenges. For a start, it is difficult to explain to the public...